News | Page 3
Daily news and information for physicians in a range of specialties and practice settings.
FDA Approves Fostamatinib for Chronic Immune Thrombocytopenia
Data revealed a response rate of 29% for those on the therapy compared to 2% with placebo, with median platelet counts at 24 weeks of 95,000/µL in the SR group, 49,000/µL in the IR group, and 20,500/µL in the non-responders.
ADHD Symptoms Linked to Risky Driving in New Teen Drivers
Teens who self-reported inattention, hyperactivity/impulsivity, and conduct disorder also reported higher risky driving behaviors.
Potential Transfer of Clostridium difficile From Dog, Cat to Household Owners
could be mutating to transfer from pets to humans.
Statins Show Protection Against Clostridium Difficile, Should Not Be Withheld in At-Risk Patients
Patients using statins had a 4.3% infection rate compared with a 7.8% rate for those not taking statins, concluding that statins may be associated with a 20% risk reduction.
Erenumab Succeeds Where Other Migraine Treatments Failed
Study results show 30.3% of difficult to treat patients taking erenumab saw at least a 50% reduction in monthly migraine days.
FDA Approves Burosumab for X-linked Hypophosphatemia, A Rare Form of Rickets
Burosumab is the first FDA approved treatment for this rare, hereditary disorder that affects 3000 children and 12,000 adults in the US.
Type 1, Not Type 2, Diabetes Rates Associated with Fast Food
The disparity of fast food swamps significantly affecting pediatric patients with T1D but not those with T2D came as a surprise to researchers.
SGLT-2 Inhibitors, GLP-1 Agonists Linked to Lower Mortality Than DPP-4 Inhibitors
SGLT-2 inhibitors and GLP-1 agonists were associated with 1% and 0.6% reductions in all-cause mortality, respectively.
FDA Approves Recombinant Therapy for Patients with von Willebrand Disease
Treatment now offers an individualized approach to control bleeding in appropriate patients undergoing surgery.
FDA Grants Breakthrough Therapy Designation to Emicizumab-kxwh
The therapy, when used prophylactically either weekly or biweekly, showed a statistically significant reduction in treated bleeds in comparison to no prophylaxis.
<< Prev Page
Next Page >>
Marijuana-Derived Cannabidiol for Seizures Receives Unanimous FDA Committee Backing
Top 10 Painkillers in the US
Dysregulation of Anti-Sense Transcription Revealed in Eye Tissues with Macular Degeneration
Can Nurse Practitioners Fill the Void in Primary Care?
What Should I Do With This Abnormal ALT?
Affordable Care Act
PHYSICIAN'S MONEY DIGEST >
MD Magazine Resources
Terms & Conditions
Copyright© MD Magazine 2006-2018 Intellisphere, LLC. All Rights Reserved.